Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the ...

In their interesting article, Ashraf et al 1 presented a modifying of the current treatment protocols for central retinal vein occlusion (CRVO). We want to address some issues directly related to the ...

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical ...

Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

Short in length, the central retinal vein courses through the optic nerve. It carries blood away from the retina toward the heart. The retina is a layer of tissue at the back of the inner eye. It is ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

U.S. Market to Reach USD 2.02 Billion and Europe Market to Hit USD 1.49 Billion by 2035 as Anti-VEGF Therapies Strengthen Vision Care.Austin, United States, June 15, 2026 (GLOBE NEWSWIRE) -- ...

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...